• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Balchem Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    3/3/25 4:18:38 PM ET
    $BCPC
    Major Chemicals
    Industrials
    Get the next $BCPC alert in real time by email
    false000000932600000093262025-02-252025-02-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 25, 2025

    Balchem Corporation
    (Exact name of registrant as specified in its charter)

    Maryland
    1-13648
    13-2578432
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    52 Sunrise Park Road, New Hampton, NY 10958
    (Address of principal executive offices) (Zip Code)

    Registrant’s telephone number, including area code: (845) 326-5600

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $.06-2/3 per share
    BCPC
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company        ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐



    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    On March 3, 2025, Balchem Corporation (the “Company”) announced that William A. Backus, Vice President and Chief Accounting Officer, has notified the Company of his intent to retire from his position on March 31, 2026.  The Company will announce Mr. Backus’ successor at a later date. There are no material changes to Mr. Backus' compensatory arrangement as a result of his planned retirement.

    Item 9.01
    Financial Statements and Exhibits.

    (d)  Exhibits

    Exhibit Number
    Description
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    BALCHEM CORPORATION
     
    (Registrant)
       
     
    By:
     /s/ Hatsuki Miyata
     
     
    Hatsuki Miyata
     
    Executive Vice President, Chief Legal Officer and Secretary
       
    Date: March 3, 2025
     



    Get the next $BCPC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCPC

    DatePrice TargetRatingAnalyst
    3/8/2022$170.00 → $155.00Buy
    HC Wainwright & Co.
    2/22/2022$175.00Neutral → Buy
    Sidoti
    1/10/2022$160.00 → $170.00Buy
    HC Wainwright & Co.
    11/29/2021$175.00Buy → Neutral
    Sidoti
    8/2/2021$140.00 → $145.00Overweight → Equal-Weight
    Stephens & Co.
    8/2/2021$145.00 → $160.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCPC
    SEC Filings

    View All

    SEC Form 10-Q filed by Balchem Corporation

    10-Q - BALCHEM CORP (0000009326) (Filer)

    7/31/25 4:17:29 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BALCHEM CORP (0000009326) (Filer)

    7/31/25 7:17:48 AM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form 11-K filed by Balchem Corporation

    11-K - BALCHEM CORP (0000009326) (Filer)

    6/24/25 4:38:30 PM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Balchem with a new price target

    HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously

    3/8/22 6:19:56 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem upgraded by Sidoti with a new price target

    Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00

    2/22/22 8:56:13 AM ET
    $BCPC
    Major Chemicals
    Industrials

    HC Wainwright & Co. reiterated coverage on Balchem with a new price target

    HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously

    1/10/22 6:15:56 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO, & Secretary Miyata Hatsuki covered exercise/tax liability with 483 shares, decreasing direct ownership by 7% to 6,189 units (SEC Form 4)

    4 - BALCHEM CORP (0000009326) (Issuer)

    7/28/25 6:15:00 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SVP and GM, Specialty Products Van Gunsteren Job Leonard was granted 2,128 shares and covered exercise/tax liability with 964 shares, increasing direct ownership by 14% to 9,446 units (SEC Form 4)

    4/A - BALCHEM CORP (0000009326) (Issuer)

    4/11/25 7:11:10 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SVP & Chief HR Officer Tignor Michael Brent was granted 3,497 shares and covered exercise/tax liability with 1,156 shares, increasing direct ownership by 35% to 9,123 units (SEC Form 4)

    4/A - BALCHEM CORP (0000009326) (Issuer)

    4/11/25 6:43:35 PM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Balchem Corporation Reports Second Quarter 2025 Financial Results

    MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor

    7/31/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

    MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch

    7/17/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation to Present at the CJS Annual New Ideas Summer Conference on July 10, 2025

    MONTVALE, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the CJS Annual New Ideas Summer Conference on July 10, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest qual

    6/26/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Leadership Updates

    Live Leadership Updates

    View All

    AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

    BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

    8/16/21 8:00:00 AM ET
    $AZRX
    $BCPC
    $BDSI
    Major Pharmaceuticals
    Health Care
    Major Chemicals
    Industrials

    $BCPC
    Financials

    Live finance-specific insights

    View All

    Balchem Corporation Reports Second Quarter 2025 Financial Results

    MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor

    7/31/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

    MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch

    7/17/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Reports First Quarter 2025 Financial Results

    MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o

    4/24/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Balchem Corporation

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    11/13/24 6:56:07 PM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    2/13/24 4:59:02 PM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    2/9/24 11:29:17 AM ET
    $BCPC
    Major Chemicals
    Industrials